Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.4. Apogee Therapeutics — Zumilokibart for Moderate-to-Severe Atopic Dermatitis (Phase 2)5. TG Therapeutics — BRIUMVI (ublituximab-xiiy) for Relapsing Forms of Multiple Sclerosis (Phase 3 ENHANCE)Apogee Therapeutics delivered a strong Phase 2 result in moderate-to-severe atopic dermatitis — 65.9% of mid-dose patients achieved a 75% reduction in disease severity at 16 weeks, compared with 23.4% on placebo. TG Therapeuticsshowed that a single Day-1 infusion of BRIUMVI gives the same drug exposure as the current two-dose initiation, simplifying multiple sclerosis treatment for thousands of patients.Catch Part 1 if you missed it. Subscribe at TrialBreaks.com#dermatology #atopicdermatitis #multiplesclerosis #neurology #biomedicine #clinicaltrials #science #medicalresearch